BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24434210)

  • 1. The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma.
    Lubanska D; Market-Velker BA; deCarvalho AC; Mikkelsen T; Fidalgo da Silva E; Porter LA
    Cancer Cell; 2014 Jan; 25(1):64-76. PubMed ID: 24434210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma.
    Parry PV; Engh JA
    Neurosurgery; 2014 Jun; 74(6):N18-9. PubMed ID: 24836103
    [No Abstract]   [Full Text] [Related]  

  • 3. SPY1-mediated symmetric cell division promotes BTIC self-renewal.
    Cancer Discov; 2014 Mar; 4(3):OF11. PubMed ID: 24596205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limits of CD133 as a marker of glioma self-renewing cells.
    Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I
    Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
    Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
    Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
    Song WC; Fei XF; Dong J
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting brain-tumor stem cells.
    Stupp R; Hegi ME
    Nat Biotechnol; 2007 Feb; 25(2):193-4. PubMed ID: 17287755
    [No Abstract]   [Full Text] [Related]  

  • 8. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
    Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
    Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathological characteristics of glioma stem cell niches.
    He H; Li MW; Niu CS
    J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD133 is a marker of bioenergetic stress in human glioma.
    Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
    PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How powerful is CD133 as a cancer stem cell marker in brain tumors?
    Cheng JX; Liu BL; Zhang X
    Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
    Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
    Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.
    Ogden AT; Waziri AE; Lochhead RA; Fusco D; Lopez K; Ellis JA; Kang J; Assanah M; McKhann GM; Sisti MB; McCormick PC; Canoll P; Bruce JN
    Neurosurgery; 2008 Feb; 62(2):505-14; discussion 514-5. PubMed ID: 18382330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology of glioma cancer stem cells.
    Park DM; Rich JN
    Mol Cells; 2009 Jul; 28(1):7-12. PubMed ID: 19655094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemoresistance of CD133(+) tumor stem cells from human brain glioma].
    Bi CL; Fang JS; Chen FH; Wang YJ; Wu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):568-73. PubMed ID: 17767043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
    Fang KM; Lin TC; Chan TC; Ma SZ; Tzou BC; Chang WR; Liu JJ; Chiou SH; Yang CS; Tzeng SF
    Glia; 2013 Sep; 61(9):1402-17. PubMed ID: 23832679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells.
    Niu CS; Li DX; Liu YH; Fu XM; Tang SF; Li J
    Oncol Rep; 2011 Sep; 26(3):593-601. PubMed ID: 21573506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
    Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
    Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
    Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cancer stem cells through L1CAM suppresses glioma growth.
    Bao S; Wu Q; Li Z; Sathornsumetee S; Wang H; McLendon RE; Hjelmeland AB; Rich JN
    Cancer Res; 2008 Aug; 68(15):6043-8. PubMed ID: 18676824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.